A powerful congressional committee is allowing a psychedelics-focused amendment to a major military bill to proceed to a floor vote in the House of Representatives—but it is also blocking other cannabis- and drug-related proposals from advancing.
The House Rules Committee on Monday considered the amendments to the National Defense Authorization Act (NDAA) for Fiscal Year 2027, allowing one that would extend a psychedelics research effort at the Department of Defense (DOD) for an additional six years to move forward.
Sponsored by Reps. Morgan Luttrell (R-TX), Jack Bergman (R-MI), Derrick Van Orden (R-WI), Mike Ezell (R-MS), Troy Carter (D-LA) and Morgan McGarvey (D-KY), Lou Correa (DCA), Seth Moulton (D-MA), Sarah Elfreth (D MD) and Michael Rulli(R-OH), the amendment seeks to include language in the bill expanding DOD studies on psychedelics that were first authorized under the earlier 2024 NDAA.
That program, signed into law by then-President Joe Biden, directed DOD to establish a process by which active duty service members with post-traumatic stress disorder (PTSD) or traumatic brain injury could participate in clinical trials involving psilocybin, MDMA, ibogaine, 5-MeO-DMT and “qualified plant-based alternative therapies.”
As enacted, it only required the secretary of defense to issue updated reports on progress within one
Read full article on Marijuana Moment
